Sarepta Therapeutics, headquartered in Cambridge, Massachusetts, is a global biotechnology company on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing.
Location: United States, Massachusetts, Cambridge
Employees: 501-1000
Phone: +1 617-274-4000
Founded date: 1980
Investors 1
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
Mentions in press and media 17
| Date | Title | Description | Source |
| 17.04.2024 | Parent Project Muscular Dystrophy Celebrates 30th Anniversar... | PPMD Together: Cincinnati Marks Three Decades of PPMD's Impact and Mayor's Proclamation Honors Found... | salamancap... |
| 02.04.2024 | Hansa Biopharma Expects Strong First Quarter 2024 Sales Perf... | Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance Tue, Apr 02, 2024 07:00 CET Repo... | news.cisio... |
| 22.03.2024 | FDA Nod in Duchenne Helps Wider Swath of Patients With the R... | Duchenne muscular dystrophy has several approved drugs, including a gene therapy that provides child... | medcitynew... |
| 21.03.2024 | Hansa Biopharma publishes 2023 Annual and Sustainability Rep... | Hansa Biopharma publishes 2023 Annual and Sustainability Reports Thu, Mar 21, 2024 07:00 CET Report ... | news.cisio... |
| 11.03.2024 | Global $111+ Billion Duchenne Muscular Dystrophy (DMD) Drugs... | - | globenewsw... |
| 09.01.2022 | Hansa Biopharma provides business update including certain k... | Hansa Biopharma provides business update including certain key financials Sun, Jan 09, 2022 08:00 CE... | news.cisio... |
| 09.11.2021 | Patient registries: A catalyst for developing new therapies ... | Patient registries are powerful tools for collecting information about a variety of conditions or th... | marketscre... |
| 03.11.2021 | Sarepta Therapeutics Announces Third Quarter 2021 Financial ... | Net product sales for the third quarter of 2021 reached $166.9 million, a 37% increase over the same... | marketscre... |
| 27.08.2021 | Sarepta Therapeutics : Measurements Used in Clinical Trials ... | Sarepta is working hard to develop precision genetic medicines for patients with rare diseases who o... | marketscre... |
| 07.11.2019 | Software companies continue the winning streak on Deloitte’s... | On the 25th anniversary of Deloitte’s Fast 500 list, software companies are still eating the world b... | techrepubl... |
Show more